Association of Serum Telomerase Activity in Type 2 Diabetes Mellitus Patients with or without Microalbuminuria

Roma Rattan1, Andrew Abel Lamare2, Sudeep Jena3, Nirmal Sahoo4, Manmath Kumar Mandal5

1, 2, 3, 4 Department of Biochemistry, SCB Medical College, Cuttack, Odisha, India.
4Department of Medicine, S.C.B. Medical College, Cuttack, Odisha, India.

ABSTRACT

BACKGROUND
Telomerase is an enzyme which helps in maintaining the length of the telomeres. Various studies have associated the telomere length and serum telomerase activity with ageing, insulin resistance and obesity. The metabolic disease type 2 diabetes mellitus is also associated with premature ageing, obesity, insulin resistance. Urine microalbuminuria is one of the frequently used markers to assess renal involvement in non-insulin dependent type 2 diabetes patients. Hence, this study was conducted to estimate the association of serum telomerase activity, a marker of aging and its association with urine microalbuminuria in non-insulin dependent type 2 diabetes patients with or without renal involvement.

METHODS
The study included 180 non-insulin dependent type 2 diabetes patients divided into two groups – Group I without microalbuminuria; Group II with microalbuminuria and 90 age and sex matched healthy volunteers as control population of the study. The sample size was determined at conveniences. Fasting blood sugar, lipid profile, serum urea, creatinine was estimated by autoanalysers, glycated haemoglobin by high performance liquid chromatography (HPLC) and serum telomerase activity were measured by enzyme-linked immunosorbent assay (ELISA) method. Urinary microalbuminuria was measured by immunoturbidimetry. The data was compared by one-way analysis of variance (ANOVA) and post hoc Tukey’s honestly significant difference (HSD) test, linear regression analysis and Pearson correlation analysis.

RESULTS
Non-insulin dependent type 2 diabetes patients with microalbuminuria had significantly lower telomerase activity and higher glycated haemoglobin, dyslipidaemia, increased serum urea and creatinine levels as compared to the group I diabetes mellitus patients and healthy volunteers. The serum telomerase level exhibited a negative correlation with urinary microalbuminuria, glycated hemoglobin and serum triglyceride and BMI.

CONCLUSIONS
Low Serum Telomerase is associated with microalbuminuria, obesity and poor glycaemic control in non-insulin dependent type 2 diabetes mellitus patients, indicating the possible existence of a common clinical profile and premature aging among diabetic patients with chronic kidney disease. Early screening for microalbuminuria and serum telomerase level may assist management of positive cases and reduce the load of chronic renal disease and coronary artery disease in type 2 diabetes patients. Validation of our observations may be done by extending the study in larger population thereby facilitating the understanding of T2DM pathophysiology and its complications.

KEYWORDS
Diabetes Mellitus, Glycated Haemoglobin, Microalbuminuria, Telomerase
Telomeres are found at the ends of chromosomes and are composed of repetitive nucleotide sequence of TTAGGG. The telomeres prevent chromosomal shortening, incomplete replication, protect the chromosomes from fusion with other adjacent chromosomes, deterioration, thus maintaining the regulatory and protein coding sequences in the genome.1,2 The telomere shortening is maintained by the enzyme telomerase, whose main components are a reverse transcriptase and an RNA template. Telomerase is responsible for ageing and is not active in mature cells.1,2 It is active in immature undifferentiated cells, few mature lymphocytes and during embryogenesis. Various factors such as age, chronic diseases such as diabetes, hypertension, cancer, chronic obstructive lung disease and renal disease have been associated with shortening of telomeres.3-5 Telomere length is also affected by oxidative and nitrosate stress.5,6 Non-insulin dependent type 2 diabetes mellitus (T2DM) is associated with increased body mass index, insulin resistance, physical inactivity & oxidative stress.6-14 Recent research has shown that T2DM and telomere have a bilateral relationship in animal studies.14-17 These facts have intensified research to evaluate telomerase activity in chronic diseases and whether it can be used therapeutically.18-23 Many T2DM patients suffer from micro and macro vascular complications such as neuropathy, cardiovascular & coronary artery disease, retinopathy, nephropathy and peripheral vascular disease such as diabetic foot ulcer.21-23

Hence, this study was conducted to estimate the telomerase activity and find its association with microalbuminuria in T2DM Patients.

**METHODS**

This case control study included 270 individuals, out of which 180 were T2DM patients (Group I – included 90 number of T2DM patients without microalbuminuria; Group II - included an equal number of T2DM patients with microalbuminuria) and 90 individuals were age and gender matched healthy volunteers who were controls. This study was conducted between September 2018 to October 2019. The sample size was as per convenient sample size due to constraints of budget and time. The study was conducted in the Molecular Diagnostic Laboratory of the Department of Biochemistry in association with the Department of Medicine, SCB Medical College, Cuttack, Odisha. The study was approved by the institute ethical committee, regd. No. ECR / 84 / Inst / OR / 2013, ICE / IRB No. 697 / 28.9.18. The inclusion criterion was as follows: All T2DM patients within the age of 25 to 65 years with confirmed diabetes mellitus as per International Diabetes Federation/ American Diabetes Association (IDF / ADA) criteria were included.24 The duration of disease in majority of the patients was within 7 years. T2DM patients with the history of myocardial disease, neuropathy, stroke, malignancy or other comorbid conditions were excluded. Patients on steroid therapy were excluded. The height, weight, waist circumference was measured, and body mass index was calculated in units of Kg / m².25

Fasting venous samples were collected in clot-activator, fluoride and ethylenediaminetetraacetic acid (EDTA) tubes. Blood sugar (hexokinase method), serum lipid profile (total cholesterol by cholesterol oxidase method; triglyceride by glycerol–3–phosphate-oxidase / peroxidase method; low density lipoprotein-cholesterol and high density lipoprotein cholesterol were measured by selective inhibition method), serum urea and creatinine was estimated by commercial kits adapted to autoanalyser to assess the renal function. Estimated glomerular filtration rate (eGFR) was calculated using Cockcroft–Gault formula: creatinine clearance = (((140 - age) x weight) / (72 x serum creatinine)) x 0.85 (if female).26 Glycated haemoglobin was estimated by HPLC method to estimate the glycaemic control of the study population in the past six weeks. Serum telomerase was estimated by Biocodon kits, Kanas, USA by Quantitative Sandwich Elisa method. Urinary microalbuminuria was measured by immunoturbidimetric method.

**Statistical Analysis**

All the data has been represented as mean ± standard deviation. The data was compared by one-way ANOVA with post hoc Tuckey HSD test, linear regression analysis and Pearson correlation analysis using Statistical Package for the Social Sciences (SPSS) version 21 software. Differences were considered significant for P < 0.05.

**RESULTS**

The demography details and the comparison of biochemical parameters is depicted in Table-I. A significant difference at P value < 0.05 was observed in biochemical parameters between the groups. Serum telomerase activity was significantly lower in the T2DM patients with renal involvement as compared to the diabetic mellitus patients without complications and healthy volunteers. The prognostic factors such as body mass index (BMI), waist circumference, glycated haemoglobin, serum creatinine and eGFR was lower in the T2DM patients with microalbuminuria. Table 2 shows the Pearson correlation of glycated haemoglobin, eGFR and urinary microalbuminuria with serum telomerase level. A significant positive correlation was observed between serum telomerase activity with eGFR, urinary microalbuminuria and Glycated haemoglobin. Figure 1 depicts the graphical representation of the tables 1 and 2. All data was represented as mean ± SD. The data was compared by one-way ANOVA followed by post hoc Tuckey HSD test. A P-value of < 0.05 was considered significant. A: depicts P-value < 0.05 between group I & III; B: depicts P value < 0.05 between group III & II; C: depicts P value < 0.05 between group I & II. A significant correlation was present between the prognostic markers and serum telomerase activity. The linear regression analysis of serum telomerase level with glycated haemoglobin and microalbuminuria revealed that serum telomerase activity level significant association with an increase in...
microalbuminuria and glycated haemoglobin (r = 0.766; P < 0.05).

Table 1. Comparison of Demographic and Biochemical Characteristics among the Different Groups

| Characteristics                  | Group I - T2DM Patients with Microalbuminuria (N-90) | Group II - T2DM Patients with Proteinuria (N-90) | Group III - T2DM Patients with Nephrotic Syndrome (N-90) | Group IV - Controls (N-90) |
|----------------------------------|-----------------------------------------------------|--------------------------------------------------|--------------------------------------------------------|---------------------------|
| Age (years)                      | 49 ± 20.2                                           | 49.8 ± 21.1                                      | 45 ± 21.2                                              | 50 ± 20.5                 |
| Gender (M / F)                   | 58 / 32                                             | 61 / 29                                          | 56 / 34                                                | 58 / 34                   |
| Duration of disease T2DM (years) | 9.29                                                | 9.31                                             | 0                                                     |                           |
| Waist circumference (cm)         | 113.8 ± 9.7                                         | 109 ± 9.1                                        | 87 ± 2.4                                               | 105 ± 2.4                 |
| Body mass index (Kg / m2)        | 29.9 ± 0.7                                          | 31.87 ± 0.7                                      | 24.1 ± 0.12                                            | 26.1 ± 0.12               |
| History of smoking (%) of individuals in a group | 58                                                  | 64                                               | 28                                                    |                           |
| Fasting blood glucose (FBS) mg % | 118 ± 14.2                                          | 159 ± 16.4                                       | 101 ± 1.2                                              |                           |
| Serum total cholesterol (TC) mg %| 166.2 ± 4.1                                         | 189.2 ± 3.9                                      | 144.8 ± 1.24                                            | 124 ± 1.24               |
| Serum triglyceride (TG) mg %     | 188.4 ± 6.2                                         | 212.4 ± 8.4                                      | 144.2 ± 1.08                                            | 134 ± 1.08               |
| Serum HD-Cholesterol (HDL-C) mg %| 42.1 ± 0.12                                         | 36.6 ± 0.97                                      | 54.9 ± 1.2                                              | 47 ± 1.26                |
| Serum LDL-Cholesterol (LDL-C) mg %| 118.4 ± 6.2                                         | 143.8 ± 5.9                                      | 96.7 ± 8.2                                              | 108 ± 8.2                |
| Glycated haemoglobin (HbA1c) %  | 7.2 ± 0.2                                           | 8.3 ± 4.5                                        | 5.6 ± 1.2                                              | 4.5 ± 1.2                |
| Serum urea mg %                 | 28 ± 1.23                                           | 32 ± 2.13                                        | 18.4 ± 2.31                                             | 16 ± 2.31                |
| Serum creatinine mg %           | 1.8 ± 0.6                                           | 2.8 ± 0.33                                       | 0.8 ± 2.48                                              | 0.8 ± 2.48               |
| Estimated glomerular filtration rate (eGFR) mL / min / 1.73 m² | 76.9 ± 5.34                                         | 54.4 ± 3.6                                       | 96 ± 2.48                                              | 106 ± 2.48               |
| Serum telomerase activity (AU)   | 883 ± 10.2                                          | 772.4 ± 0.8                                      | 1608 ± 149.5                                            | 1908 ± 149.5             |

Table 2. Pearson Correlation Analysis between Prognostic Parameters and Serum Telomerase

| Prognostic Parameters               | Serum Telomerase Activity R2 | P-Value |
|-------------------------------------|-----------------------------|---------|
| Glycated hemoglobin                 | -0.894                      | < 0.05  |
| Estimated glomerular filtration rate| 0.882                       | < 0.05  |
| Urinary microalbuminuria            | -0.856                      | < 0.05  |

DISCUSSION

This study aimed at evaluating the serum telomerase activity in type 2 DM with or without microalbuminuria. We observed hyperglycaemia, poor glycaemic control increases serum triglycerides and decrease in serum telomerase activity in the T2DM patients. The hyperglycaemic and increased serum fatty acids lead to deposition of fatty acids in non-adipose tissues and disrupt the homeostasis of oxidative stress pathway. It also activates the PKC pathway thereby causing phosphorylation, inhibition of insulin signalling pathway.27,28 Our study observed increase in truncal obesity as the waist circumference is comparatively higher in the T2DM patients. An increase in adipose tissue stimulates various inflammatory cytokines such as interleukin-1, interleukin-6 and tumour necrosis factor alpha which causes activation of NF-κB and c-Jun N-terminal kinase and increase the insulin resistance, obesity and metabolic syndrome thereby resulting in chronic inflammation and oxidative stress. In our study, we found an increased in serum triglyceride level which was associated inversely with serum telomerase level.

The BMI and waist circumference of the patient population was also inversely correlated with the serum telomerase level. This shows truncal obesity adversely affects the balance of telomerase function. This observation is in congruence with previous studies by Daubenmier J. et al and Hamel et al.27,28 The enzyme telomerase is also known as terminal transferase is a ribonucleoprotein complex and helps to maintain the length of the telomeric part of the chromosome.26 The telomeric shortening occurs with age and hence the telomerase activity is reduced or absent in mature somatic cells which results in the death of the cells. The telomerase activity is highest during gestation and in immature cells.28,26

In chronic diseases such as non-insulin dependent type 2 diabetes mellitus, chronic renal disease there occurs increased production and secretion of proinflammatory cytokines like interferon γ, interleukin 6 and tumour necrosis factor alpha etc. This leads to a dysfunction in the telomerase activity. The inflammation and oxidative stress alter the telomerase activity, decrease the telomere length affect the development and functioning of both the alpha and beta islet cells leading to T2DM. Inflammation and reduced telomerase activity also causes endothelial cell dysfunction leading to renal impairment, Figure-1. Our study shows that in diabetic patients along with glycaemic control, the presence of increased triglycerides and truncal obesity contribute to decrease in the serum telomerase level.

The study used microalbuminuria as a marker for detecting target organ damage by T2DM. Microalbuminuria is an early marker of renal glomerular dysfunction. In T2DM case microalbuminuria is most often used to ascertain the involvement of target organ damage. In this study, we observed an inverse relation of serum telomerase activity with microalbuminuria and glycated haemoglobin. This implies that an impaired glycaemic control is associated with target organ damage and decreased telomerase function, but we were unable to explain whether this was the cause or consequence.

Various studies have associated the telomere length and serum telomerase activity with ageing, insulin resistance and...
obesity. We observed a decrease in serum telomerase activity in the T2DM patients, which further decreased in the T2DM patients with nephropathy. This decrease is irrespective of gender and age. Studies in the past have suggested that telomerase level decreases with age but we observed that the level of decrease is more in association with the glycated haemoglobin. The increase in glycaemic control of the T2DM patients had an adverse impact on the serum telomerase level in our study and it was in agreement with the study by Vasran et al. Studies have suggested a decrease in telomerase activity in the obesity. We too observed an increase in the body mass index in the T2DM patients who had a decrease in telomerase activity. This suggests that obesity in T2DM leads to a pro-inflammatory status, increasing the release of pro-inflammatory cytokines, increasing oxidative stress and deranging the telomerase-telomere system implicating a higher susceptibility of end organ damage.

CONCLUSIONS

The observations of our study indicate that serum telomerase activity plays an important role in T2DM disease progression and target organ damage; hence, it might be considered as a perspective therapeutic agent. T2DM patients with poor glycemc control have increased serum triglyceride, truncal obesity, microalbuminuria and decreased serum telomerase activity, thereby making the patients susceptible to both cardiovascular and peripheral vascular diseases. Therefore, estimation of serum telomerase level in these patients will help prevent these future complications in the T2DM patients.

Data sharing statement provided by the authors is available with the full text of this article at jebmh.com.

Financial or other competing interests: Authors report grants from Medical Research Unit (MRU) SCB Medical College, Cuttack, during the conduct of the study. Authors thank the staff of Multidisciplinary Research Unit of SCB Medical College for funding the kits for this study. Disclosure forms provided by the authors are available with the full text of this article at jebmh.com.

The authors thank the patients, the volunteers, the technicians and data entry operators for participating in the study.

REFERENCES

[1] Elks CE, Scott RA. The long and short of telomere length and diabetes. Diabetes 2014;63(1):65-67.
[2] Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345(6274):458-460.
[3] Slagboom PE, Droog S, Boomsma DI. Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet 1994;55(5):876-882.
[4] Von Zglinicki T, Martin-Ruiz CM. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med 2005;5(2):197-203.
[5] Petersen S, Saretzki G, von Zglinicki T. Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. Exp Cell Res 1998;239(1):152-160.
[6] Matthews C, Gorennne I, Scott S, et al. Vascular smooth muscle cells undergo telomere-based senescence in human atherosclerosis: effects of telomerase and oxidative stress. Circ Res 2006;99(2):156-164.
[7] Hansel B, Giral P, Nobecourt E, et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidant activity. J Clin Endocrinol Metab 2004;89(10):4963-4971.
[8] Ilić AC, Alexa ID, Morošanu AI, et al. Effects of oxidative stress and pharmacological treatment on geriatric syndromes in the hospitalized elderly patients. Farmacia 2016;64:588-593.
[9] Totan A, Greabu M, Mitrea M, et al. Relationships between erythrocyte Na+/K+-ATPase activity, oxidative stress and high blood pressure in hypertensive diabetic patients. Farmacia 2010;58(3):322-331.
[10] Tzanetakou IP, Katsilambros NL, Benetos A, et al. Is obesity linked to aging? Adipose tissue and the role of telomeres. Ageing Res Rev 2011;11(2):220-229.
[11] Ghibu S, Ilie I, Mureşan A, et al. Perspectives in the experimental study of the metabolic syndrome. Farmacia 2015;63(4):482-486.
[12] Gardner JP, Li S, Srinivasan SR, et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation 2005;111(17):2171-2177.
[13] Cherkas LF, Hunkin JI, Kato BS, et al. The association between physical activity in leisure time and leukocyte telomere length. Arch Intern Med 2008;168(2):154-158.
[14] Kuhlow D, Florian S, von Figura G, et al. Telomerase deficiency impairs glucose metabolism and insulin secretion. Aging (Albany NY) 2010;2(10):650-658.
[15] Serra V, Grune T, Sitte N, et al. Telomere length as a marker of oxidative stress in primary human fibroblast cultures. Ann N Y Acad Sci 2000;908:327-330.
[16] Salpea KD, Talmud PJ, Cooper JA, et al. Association of telomere length with type 2 diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis 2010;209(1):42-50.
[17] Zhao J, Miao K, Wang H, et al. Association between telomere length and type 2 diabetes mellitus: a meta-analysis. PLoS One 2013;8:e79993.
[18] Sharma R, Gupta A, Thungapathra M, et al. Telomere mean length in patients with diabetic retinopathy. Sci Rep 2015;5:18368.
[19] Fyhquist F, Titu A, Sajinomaa O, et al. Telomere length and progression of diabetic nephropathy in patients with type 1 diabetes. J Intern Med 2010;267(3):278-286.
[20] Dудinskaya EN, Tkacheva ON, Shestakova MV, et al. Short telomere length is associated with arterial aging in patients with type 2 diabetes mellitus. Endocrinol Connect 2015;4(3):136-143.
[21] Boulton AJM. The diabetic foot: epidemiology, risk factors and epidemiology, risk factors and the status of care. Diabetes Voice 2005;50(Suppl 1):5-7.
[22] Lu B, Yang Z, Wang M, et al. High prevalence of diabetic neuropathy in population-based patients diagnosed with type 2 diabetes in the Shanghai downtown. Diabetes Res Clin Pract 2010;88(3):289-294.

[23] Baltzis D, Roustit M, Grammatikopoulou MG, et al. Diabetic peripheral neuropathy as a predictor of asymptomatic myocardial ischemia in type 2 diabetes mellitus: a cross-sectional study. Adv Ther 2016;33(10):1840-1847.

[24] American Diabetes Association: Standards of medical care in diabetes - 2015 abridged for primary care providers. Clin Diabetes 2015;33(2):97-111.

[25] Pham H, Armstrong DG, Harvey C, et al. Screening techniques to identify people at high risk for diabetic foot ulceration: A prospective multicenter trial. Diabetes Care 2000;23(5):606-611.

[26] World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. World Health Organization, Geneva. 2015.

[27] Daubenmier J, Lin J, Blackburn E, et al. Changes in stress eating and metabolic factor are related to changes in telomerase activity in randomized mindful intervention pilot study. Psychoneuroendocrinology 2012;37(7):917-928.

[28] Hamel FG. Telomeres and type 2 diabetes. Transl Res 2010;155(4):164-165.

[29] Vasan RS, Demissie S, Kimura M, et al. Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the Framingham Heart Study. Circulation 2008;117(9):1138-1144.

[30] Valdes AM, Andrew T, Gardner JP, et al. Obesity, cigarette smoking and telomere length in women. Lancet 2005;366(9486):662-664.